The instinct when revising paediatric pharmacology is to learn the drugs: the classes, the mechanisms, the side effects, much as you did for adults, with a mental note to divide the dose. That instinct will get you through some of the paper and fail you on the questions that distinguish this specialty, because paediatric pharmacology is not a scaled adaptation of adult pharmacology. The child's absorption, distribution, metabolism and excretion all differ from the adult's, they differ differently at each age, and the exam is built precisely on those differences.
Key takeaways
- Learn the developing body first, because it explains most of the paediatric drug behaviour you would otherwise memorise.
- Neonates are not small children: their hepatic and renal handling differs enough to change dose and interval.
- Weight-based dosing has ceilings, and knowing when the adult maximum applies is examinable.
- Some adverse effects are specific to children and to growing tissue, and they recur in the exam.
- Build the mechanism first, then generate the clinical case, rather than reading a comparison table.
Start with the developing body
Almost every paediatric pharmacology fact you might memorise is a consequence of developmental physiology, which means you can derive it instead.
Absorption. Gastric pH, gastric emptying and intestinal transit all differ in infancy, which changes oral bioavailability. Skin is thinner and the surface-area-to-weight ratio is higher, which is why topical agents are absorbed far more readily and why topical steroid toxicity is a real paediatric problem and a favourite exam theme.
Distribution. Body composition changes dramatically with age. Neonates have a much higher proportion of total body water and less fat, which changes the volume of distribution of water-soluble and lipid-soluble drugs in opposite directions. Protein binding is lower in the neonate, so the free fraction of highly bound drugs is higher, which matters for the drugs where the free fraction is what acts and what harms.
Metabolism. Hepatic enzyme systems mature at different rates after birth, and some are immature for weeks or months. This is why certain drugs have prolonged half-lives in neonates and why some are simply avoided.
Excretion. Glomerular filtration is low at birth and rises over the first months. Renally cleared drugs therefore accumulate in the neonate at doses that would be entirely safe later.
Learn those four, in that order, and a great deal of what otherwise looks like arbitrary paediatric drug trivia becomes predictable.
The neonate is a separate pharmacological population
This is worth stating separately because candidates blur it.
A neonate is not a small infant, and an infant is not a small child. The differences above are most extreme in the first weeks of life and change fast during them, which means age in days matters, gestational age matters, and prematurity matters enormously.
The exam constructs questions around exactly this, presenting a drug that would be entirely appropriate at six months and asking about it in a two-week-old, or presenting a premature infant and expecting you to know that the usual rules do not apply.
Weight-based dosing, and its ceilings
Paediatric doses are calculated from weight, and the exam tests the calculation.
But two subtleties trip candidates. The first is the ceiling: weight-based dosing does not continue upward indefinitely, and at some point the adult maximum dose applies, so a large adolescent does not receive a supra-adult dose because the arithmetic says so. Knowing when the cap applies is examinable.
The second is the choice of weight. Actual body weight, ideal body weight and body surface area are used in different circumstances, and using the wrong one, particularly in an obese child, produces a dangerous answer.
Practise these as calculations under time pressure, and check the plausibility of the result. A number that would be an implausible dose for any child is an arithmetic error you can catch for free.
The adverse effects that are paediatric
Some toxicities exist because the patient is growing, and they recur in the exam because they are specific to the specialty.
Effects on growth, whether from corticosteroids or from other agents, and the monitoring that follows. Effects on developing bone and cartilage, and the drugs that are avoided for that reason. Effects on developing teeth. Neurodevelopmental effects. The specific hazards of drugs in the neonate that are not hazards later, including the classic examples where an immature metabolic pathway leads to accumulation and toxicity.
And the paediatric-specific contraindications, which every candidate is expected to know cold and which are a reliable source of questions.
Build the case, do not read the table
A method point, because it determines whether any of this survives to the exam.
Comparison tables are useful for a first pass and produce almost no retention, because reading a table is receptive and the exam requires you to generate.
So having built the table, close it, and generate the clinical case yourself. Take a mechanism, invent a child, and ask what happens. "This drug is renally cleared. My patient is three weeks old. Therefore the half-life is prolonged, therefore I extend the interval, therefore I watch for accumulation, and the sign of accumulation would be this."
That generative act is what makes pharmacology stick, and it is precisely what the vignette in the exam will ask you to do.
Where iatroX fits
iatroX's MRCPCH TAS bank presents pharmacology inside clinical vignettes rather than as isolated recall, which is how the exam presents it, and its explanations are grounded in current guidance including the summary of product characteristics, so the reason a drug is contraindicated at a given age sits with the question. Missed questions can be opened in the Socratic Tutor, which asks you to reason from the developmental physiology before it explains, and spaced repetition returns the paediatric contraindications and dose ceilings that decay fastest. Try it with free sample questions at iatroX. For the general method of predicting rather than recalling, see turning paediatric science into clinical predictions.
Frequently asked questions
Is paediatric pharmacology just adult pharmacology at a lower dose? No, and treating it that way is the commonest error. Absorption, distribution, metabolism and excretion all differ in children, differ again in neonates, and change with age, which is exactly what the exam is built around.
Why are neonates treated as a separate pharmacological population? Because hepatic enzyme systems and glomerular filtration are immature at birth and mature over weeks to months, so renally cleared and hepatically metabolised drugs accumulate at doses that would be safe later. Gestational age and prematurity matter too.
Does weight-based dosing continue indefinitely? No. There is a ceiling at which the adult maximum dose applies, so a large adolescent should not receive a supra-adult dose because the arithmetic suggests it. Knowing when the cap applies is examinable, as is choosing between actual weight, ideal weight and surface area.
How should I learn drug comparisons? Build the table once, then close it and generate clinical cases from the mechanism yourself. Reading a table is receptive and produces little retention; generating the consequence for a specific child is what the exam asks you to do and what makes the knowledge stick.